Bococizumab
- Product Name
- Bococizumab
- CAS No.
- 1407495-02-6
- Chemical Name
- Bococizumab
- Synonyms
- Bococizumab;RN316|||PF-04950615;Bococizumab 6.17mg/ml;Bococizumab (anti-PCSK9);Research Grade Bococizumab;Research Grade Bococizumab(DHJ24004)
- CBNumber
- CB68080899
- Formula Weight
- 0
- MOL File
- Mol file
Bococizumab Property
- form
- Liquid
- color
- Colorless to light yellow
Bococizumab Chemical Properties,Usage,Production
Uses
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].
in vivo
Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development[2].
| Animal Model: | Pregnant Sprague-Dawley (SD) rats[1] |
| Dosage: | 0, 10, 30, and 100 mg/kg |
| Administration: | Intravenous injection (i.v.) |
| Result: | Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters. |
References
[1] Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505. DOI:10.1253/circj.CJ-16-1310
[2] Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70. DOI:10.1016/j.yrtph.2015.08.007